Semaglutide mimics the activity of the GLP-1 hormone that regulates your bodys sugar level and metabolism and occupies its receptors
For patients who believe that medication alone isn't sufficient for sustainable results, Calibrates model is appealing
J Nanobiotechnology 2025;23:682
The future of GLP-1s lies in addressing these disparities, not only in access, but in how we approach obesity care in general
Additionally, combination drugs can address multiple aspects of obesity and related conditions in a single treatment, improving convenience and adherence
They are designed for individuals who are at a stable, healthy weight but struggle with localised pockets of stubborn fat, such as a double chin or love handles, that resist traditional diet and exercise